Literature DB >> 15182352

Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris.

Marie-Louise Zani1, Shila M Nobar, Sandrine A Lacour, Soazig Lemoine, Christian Boudier, Joseph G Bieth, Thierry Moreau.   

Abstract

Elafin and its precursor, trappin-2 or pre-elafin, are specific endogenous inhibitors of human neutrophil elastase and proteinase 3 but not of cathepsin G. Both inhibitors belong, together with secretory leukocyte protease inhibitor, to the chelonianin family of canonical protease inhibitors of serine proteases. A cDNA coding either elafin or its precursor, trappin-2, was fused in frame with yeast alpha-factor cDNA and expressed in the Pichia pastoris yeast expression system. Full-length elafin or full-length trappin-2 were secreted into the culture medium with high yield, indicating correct processing of the fusion proteins by the yeast KEX2 signal peptidase. Both recombinant inhibitors were purified to homogeneity from concentrated culture medium by one-step cationic exchange chromatography and characterized by N-terminal amino acid sequencing, Western blot and kinetic studies. Both recombinant elafin and trappin-2 were found to be fast-acting inhibitors of pancreatic elastase, neutrophil elastase and proteinase 3 with k(ass) values of 2-4 x 10(6) m(-1).s(-1), while dissociation rate constants k(diss) were found to be in the 10(-4) s(-1) range, indicating low reversibility of the complexes. The equilibrium dissociation constant K(i) for the interaction of both recombinant inhibitors with their target enzymes was either directly measured for pancreatic elastase or calculated from k(ass) and k(diss) values for neutrophil elastase and proteinase 3. K(i) values were found to be in the 10(-10) molar range and virtually identical for both inhibitors. Based on the kinetic parameters determined here, it may be concluded that both recombinant elafin and trappin-2 may act as potent anti-inflammatory molecules and may be of therapeutic potential in the treatment of various inflammatory lung diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182352     DOI: 10.1111/j.1432-1033.2004.04156.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  20 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Three-dimensional Structure of a Kunitz-type Inhibitor in Complex with an Elastase-like Enzyme.

Authors:  Rossana García-Fernández; Markus Perbandt; Dirk Rehders; Patrick Ziegelmüller; Nicolas Piganeau; Ulrich Hahn; Christian Betzel; María de Los Ángeles Chávez; Lars Redecke
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

3.  Pseudomonas aeruginosa proteolytically alters the interleukin 22-dependent lung mucosal defense.

Authors:  Antoine Guillon; Deborah Brea; Eric Morello; Aihua Tang; Youenn Jouan; Reuben Ramphal; Brice Korkmaz; Magdiel Perez-Cruz; Francois Trottein; Richard J O'Callaghan; Philippe Gosset; Mustapha Si-Tahar
Journal:  Virulence       Date:  2016-10-28       Impact factor: 5.882

4.  A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.

Authors:  Donna M Small; Marie-Louise Zani; Derek J Quinn; Sandrine Dallet-Choisy; Arlene M A Glasgow; Cecilia O'Kane; Danny F McAuley; Paul McNally; Sinéad Weldon; Thierry Moreau; Clifford C Taggart
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

5.  Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases.

Authors:  Nicolas Guyot; Gudmundur Bergsson; Marcus W Butler; Catherine M Greene; Sinéad Weldon; Efrat Kessler; Rodney L Levine; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  Biol Chem       Date:  2010-06       Impact factor: 3.915

6.  Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid.

Authors:  O Laugisch; M Schacht; A Guentsch; T Kantyka; A Sroka; H R Stennicke; W Pfister; A Sculean; J Potempa; S Eick
Journal:  Mol Oral Microbiol       Date:  2011-12-07       Impact factor: 3.563

7.  Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema.

Authors:  Alain Doucet; Dominique Bouchard; Marie France Janelle; Audrey Bellemare; Stéphane Gagné; Guy M Tremblay; Yves Bourbonnais
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

Review 8.  Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

9.  Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.

Authors:  Nicolas Guyot; Marcus W Butler; Paul McNally; Sinead Weldon; Catherine M Greene; Rodney L Levine; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

10.  Effects of the neutrophil elastase inhibitor EL-17 in rat adjuvant-induced arthritis.

Authors:  Lorenzo Di Cesare Mannelli; Laura Micheli; Lorenzo Cinci; Mario Maresca; Claudia Vergelli; Alessandra Pacini; Mark T Quinn; Maria Paola Giovannoni; Carla Ghelardini
Journal:  Rheumatology (Oxford)       Date:  2016-03-30       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.